NCT05304169View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 14, 2017

Primary Completion Date

June 15, 2018

Study Completion Date

June 15, 2020

Conditions
Prostate Cancer
Interventions
DRUG

Leuprorelin Acetate (Eligard® 45 mg).

Semiannually Leuprorelin Acetate (Eligard® 45 mg).

Trial Locations (6)

Unknown

CPMEC - Hospital Nossa Senhora da Conceição, Porto Alegre

HCB - Hospital do Câncer de Barretos, Barretos

Hospital Amaral Carvalho, Jaú

CIP - Centro Integrado de Pesquisa, São José do Rio Preto

ICESP - Instituto do Câncer do Estado de São Paulo, São Paulo

IAMSPE - Instituto de Assistência Médica ao Servidor Público Estadual de S. Paulo, São Paulo

All Listed Sponsors
lead

Zodiac Produtos Farmaceuticos S.A.

INDUSTRY

NCT05304169 - Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual. | Biotech Hunter | Biotech Hunter